Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nidal Al-Huniti

Showing results (21-30 of 52) with videos related to

Pageof 6
Sort By:
Journal of Clinical Pharmacology|August 7, 2015
The effect of quinidine, a strong P-glycoprotein inhibitor, on the pharmacokinetics and central nervous system distribution of naloxegolKhanh Bui, Fahua She, Diansong Zhou, et al.
Journal of Clinical Pharmacology|August 14, 2018
Population Pharmacokinetic and Exposure-Response Analysis of Selumetinib and Its N-desmethyl Metabolite in Patients With Non-Small Cell Lung CancerXiao Tong, Hongmei Xu, David J Carlile, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 8, 2017
Population Exposure-Response Modeling Supported Selection of Naloxegol Doses in Phase III Studies in Patients With Opioid-Induced ConstipationNidal Al-Huniti, Hongmei Xu, Diansong Zhou, et al.
Pharmaceutical Statistics|January 12, 2018
Integrating dose estimation into a decision-making framework for model-based drug developmentJames Dunyak, Patrick Mitchell, Bengt Hamrén, et al.
Journal of Clinical Pharmacology|January 11, 2014
Population pharmacokinetics of TC-5214, a nicotinic channel modulator, in phase I and II clinical studiesHongmei Xu, Anja Henningsson, Sofie Alverlind, et al.
Biopharmaceutics & Drug Disposition|March 4, 2017
Development of a physiologically based pharmacokinetic model to predict the effects of flavin-containing monooxygenase 3 (FMO3) polymorphisms on itopride exposureWangda Zhou, Helen Humphries, Sibylle Neuhoff, et al.
Journal of Clinical Pharmacology|June 6, 2017
Population Pharmacokinetic Analysis of Zolmitriptan and Its Metabolite in Adults and Adolescents to Support Dose Selection in Children With MigraineWangda Zhou, Jianguo Li, Bruce Birmingham, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|September 4, 2019
Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese, Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically-based pharmacokinetic modellingLi Zhou, Pradeep Sharma, Karen Rowland Yeo, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 27, 2020
Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future OpportunitiesNidal Al-Huniti, Yan Feng, Jingyu Jerry Yu, et al.
Clinical Pharmacokinetics|December 18, 2018
Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell MalignanciesHelena Edlund, Sun Ku Lee, Marilee A Andrew, et al.
Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
Journal of Clinical Pharmacology|August 7, 2015
The effect of quinidine, a strong P-glycoprotein inhibitor, on the pharmacokinetics and central nervous system distribution of naloxegolKhanh Bui, Fahua She, Diansong Zhou, et al.
Journal of Clinical Pharmacology|August 14, 2018
Population Pharmacokinetic and Exposure-Response Analysis of Selumetinib and Its N-desmethyl Metabolite in Patients With Non-Small Cell Lung CancerXiao Tong, Hongmei Xu, David J Carlile, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 8, 2017
Population Exposure-Response Modeling Supported Selection of Naloxegol Doses in Phase III Studies in Patients With Opioid-Induced ConstipationNidal Al-Huniti, Hongmei Xu, Diansong Zhou, et al.
Pharmaceutical Statistics|January 12, 2018
Integrating dose estimation into a decision-making framework for model-based drug developmentJames Dunyak, Patrick Mitchell, Bengt Hamrén, et al.
Journal of Clinical Pharmacology|January 11, 2014
Population pharmacokinetics of TC-5214, a nicotinic channel modulator, in phase I and II clinical studiesHongmei Xu, Anja Henningsson, Sofie Alverlind, et al.
Biopharmaceutics & Drug Disposition|March 4, 2017
Development of a physiologically based pharmacokinetic model to predict the effects of flavin-containing monooxygenase 3 (FMO3) polymorphisms on itopride exposureWangda Zhou, Helen Humphries, Sibylle Neuhoff, et al.
Journal of Clinical Pharmacology|June 6, 2017
Population Pharmacokinetic Analysis of Zolmitriptan and Its Metabolite in Adults and Adolescents to Support Dose Selection in Children With MigraineWangda Zhou, Jianguo Li, Bruce Birmingham, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|September 4, 2019
Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese, Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically-based pharmacokinetic modellingLi Zhou, Pradeep Sharma, Karen Rowland Yeo, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 27, 2020
Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future OpportunitiesNidal Al-Huniti, Yan Feng, Jingyu Jerry Yu, et al.
Clinical Pharmacokinetics|December 18, 2018
Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell MalignanciesHelena Edlund, Sun Ku Lee, Marilee A Andrew, et al.
Pageof 6